Introduction: The association between Parkinson Disease (PD) and REM sleep behavior disorder (RBD) has been related to a specific, malignant clinical phenotype. Definite RBD diagnosis requires videopolysomnography that is often unfeasible. A malignant clinical PD-RBD phenotype could be expected also in PD patients with probable RBD. Aim of this cross-sectional study was to evaluate whether a more severe neuropsychological and functional neuroimaging phenotype can be identified in PD patients with probable RBD. Methods: Thirty-eight de novo, drug naïve PD patients underwent a first-line clinical assessment and a second-line multimodal assessment, including neuropsychological evaluation, 123 I-FP-CIT-SPECT and 18 F-FDG-PET, which were compared between PD patients with (PD þ RBDþ) and without (PD þ RBD-) probable RBD.
Parkinson's Disease (PD) typically affects aged people and is characterized by core motor features often associated with nonmotor manifestations [1] . There is increasing evidence that PD is heterogeneous in its clinical presentation and prognosis, and PD subtype identification has been delineated as one of the top three clinical research priorities [2] . Recently, a prospective cohort study has defined three clinical PD subtypes, namely mainly motor/slow progression, diffuse/malignant, and intermediate [3] . The PD clinical subtypes were defined at the baseline visit in a movement disorders clinic and the presence of mild cognitive impairment (MCI), orthostatic hypotension and REM sleep behavior disorder (RBD) identified the diffuse/malignant subtype [3] . Defining different disease subtypes since baseline could help physicians in predicting disease course and eventually designing more efficient personalized management strategies. Moreover, identifying neuroimaging features related to the different clinical subtypes could improve the understanding of the underlying disease mechanisms.
RBD is characterized by vocalization and complex motor behaviors in association with loss of normal atonia during REM sleep [4] and can appear before, simultaneously, or after the onset of PD motor symptoms [5] . The diagnostic gold-standard for RBD is the polysomnography [6] . However, overnight polysomnography is often unfeasible in clinical practice because it is time consuming, expensive, and sometimes not complied by patients, especially those with concomitant anxiety and/or cognitive impairment. A diagnosis of probable RBD can be confidently based on a typical clinical history of dream-enacting behaviors, especially in PD patients that have a high likelihood of developing RBD [7] .
Within the diffuse/malignant PD subtype, the presence of RBD has been associated with cognitive impairment [8] , autonomic dysfunction [9] , prevalence of akinetic-rigid syndrome [9] and a longer disease duration [9] . Some functional neuroimaging features have also been related to RBD. We recently reported that de novo, drug naïve PD patients with RBD show more severe nigro-striatal dopaminergic impairment, especially at caudate level, compared with PD patients without RBD [10] , suggesting a specific and more severe neurodegenerative process underlying the association between RBD and PD. It is intriguing that this neuroimaging phenotype was already found at the time of diagnosis. Recently, a 18 F-
study has found decreased glucose metabolism in posterior cortical regions, with relatively increased activity in pons, hippocampus/ parahippocampus and frontal regions in idiopathic RBD (iRBD) patients [11] . This metabolic pattern moderately overlaps the PDrelated covariance pattern [12] , which has been found to predict subsequent phenoconversion of iRBD patients to a synucleinopathy [13] . However, brain metabolic features of patients with concomitant PD and RBD have not been analyzed yet.
In this cross-sectional study, we prospectively investigated drug naïve patients with de novo PD at their first evaluation in a movement disorder unit. At the baseline visit, we performed a 'first-line' clinical, motor and cognitive assessment, including the investigation of presence/absence of probable RBD. Thus, a 'second-line' assessment, including an extensive neuropsychological evaluation and functional neuroimaging scans evaluating nigro-striatal dopaminergic functioning and brain glucose metabolism, was performed within two months since the baseline visit. We compared clinical, neuropsychological, nigro-striatal dopaminergic and brain metabolism features between PD patients either with or without probable RBD.
We hypothesized that PD patients with probable RDB, as identified with a simple questionnaire, exhibit a more severe clinical, neuropsychological and functional neuroimaging phenotype in comparison with PD patients without RBD. Aim of the study was to evaluate whether first-and second-line assessments were different between the two groups.
Methods
Forty-nine consecutive outpatients with de novo, drug-naïve PD were prospectively evaluated. Patients were at their first assessment in a University Hospital-based movement disorder unit. Diagnosis of PD followed current criteria [14] . The patients underwent brain magnetic resonance imaging (MRI), or computed tomography (CT) in the case MRI was unfeasible, to rule out other brain diseases. Patients with brain infarcts on MRI/CT or with a history of stroke or transient ischemic attacks were excluded, whereas the presence of small white matter hyperintensities on MRI was not an exclusion criterion if they did not involve the basal ganglia and/or the pons-mesencephalon.
The 'first-line' assessment performed during the baseline visit included i) the assessment of motor severity by means of the Unified Parkinson's Disease Rating Scale, motor section (UPDRS-III) and the Hoehn and Yahr stage. Patients with prevalence of tremor or prevalence of akinetic-rigid symptoms were labeled as affected by 'tremoric PD 0 or 'akinetic-rigid PD 0 , respectively; ii) the 15-item geriatric depression scale (GDS) to rate depression; iii) clinical interview with patient and informant and questionnaires for activities of daily living (ADL) and instrumental ADL to exclude dementia; iv) the Mini-Mental State Examination (MMSE) as a measure of global cognition; v) automatic blood pressure measurements both in the supine position and after 3 min of standing. Orthostatic hypotension was defined as a systolic blood pressure drop of !20 mmHg and/or a diastolic blood pressure drop of !10 mmHg during standing after 3 min [15] ; vi) investigation of presence/absence of constipation, urinary and sexual dysfunction with the clinical interview; vii) the Smell Diskettes Olfaction test [16] ; viii) the Mayo sleep questionnaire (MSQ) [17] and a structured clinical interview by a sleep medicine expert to investigate the presence/absence of probable RBD (including the question 'Have you ever been told, or suspected yourself, that you seem to 'act out your dreams' while asleep (for example, punching, flailing your arms in the air, making running movements, etc.?)'. With the aim to be as much accurate as possible without PSG, we choose to exclude from the study nine patients without a bed-partner.
The remaining forty patients underwent 6 months-based clinical follow-up (FU) after the baseline evaluation. A FU of at least one year was requested to confirm the PD diagnosis, which was confirmed in thirty-eight patients (FU ranging from 1 to 8 years, mean 3.6 ± 2.4). In two instances basal FDG-PET visual analysis was suspected for an atypical Parkinsonian syndrome that was indeed diagnosed during the follow-up (Multiple System Atrophy in one patient and Progressive Supranuclear Palsy in another one, initially belonging to the PD þ RBDþ and PD þ RBD-groups, respectively). The thirty-eight PD patients were treated with dopamine agonists and/or L-DOPA during the FU period. The patients were divided into PD patients with probable RBD (PD þ RBDþ; 24 patients) and PD patients without probable RBD (PD þ RBD-; 14 patients). Nineteen (50%) out of these 38 patients were included in a previous study [10] , dealing with clinical and nigrostriatal function but not reporting FDG-PET data.
Within two months since the baseline assessment, the 'secondline' evaluation was performed as follows. Patients underwent a neuropsychological test battery, including: (i) categorical and phonological verbal fluency; (ii) Trailmaking test A and B and Stroop color and color-word test for executive functions; (iii) figure copying of the mental deterioration battery (simple copy and copy with guiding landmarks) and Clock Completion test to assess visuospatial abilities; (iv) Rey Auditory Verbal Memory Test (RAVLT, immediate and delayed recall) and Corsi's block design to investigate memory; (v) digit span (forward) and symbol-digit to asses attention and working memory. References for tests and normative values are listed in a previous paper [18] . The presence of MCI was evaluated according to current criteria [19] by using a 1.5 standard deviation cut-off threshold below the mean value in healthy subjects.
Nigro-striatal functioning was evaluated by means of 123 I-FP-CIT Single Photon Emission Computed Tomography (SPECT) according to the European Association of Nuclear Medicine (EANM) guidelines [20] . Specific to non-displaceable binding ratios (SBRs) at putamen and caudate levels were computed and transformed into z-scores, adjusted for age, based on the European normative database [21] as detailed in a previous paper [10] . Briefly,
123
I-FP-CIT images were exported in analyze format and processed by the automatic BasGan algorithm based on a high-definition, threedimensional striatal template derived from the Talairach atlas, using the uptake of occipital lobes as the background reference region to compute SBRs.
Brain metabolism was evaluated by means of 18 F-FDG-PET according to EANM guidelines [22] . Injection, acquisition and image reconstruction protocols are detailed in a previous paper [23] . Scans were visually analyzed by two nuclear medicine experts (S.M. and F.N.) and were consistent with the diagnosis of PD in all the 38 patients. In order to highlight findings in the more (MAH) and in the less (LAH) affected hemispheres, respectively, the MAH was defined as the contralateral one to the side of the body with prevalence of motor symptoms. In 20 patients the MAH was the left one, thus, 18 Forty-nine healthy subjects (16 males; mean age 67.8 ± 11.6; p < 0.01 as compared with gender distribution in PD patients by the chi-square test) were used as the control group for 18 F-FDG-PET comparison with PD groups to assess brain metabolism differences between the two PD groups and normal subjects. Clusters showing significant differences were then submitted to post-hoc direct comparison between the two patient groups. Indeed, an a priori selection of limited clusters for direct comparison would have been unwarranted by the present knowledge. Brain 18 F-FDG-PET was compared between controls, PD þ RBDand PD þ RBD þ patients by univariate analysis of variance (ANOVA; statistical parametric mapping, SPM12; age as nuisance variable; gender was not included given the more controversial effect on brain metabolism, especially in older age [24] ). In order to exclude white matter voxels and to limit the amount of voxels from hypometabolic regions from the reference value of the global mean, we fixed a 'grey matter threshold' of 1.0 instead of the default value of 0.8 [25] . This procedure is aimed at reducing the risk that findings indicating increased FDG uptake are artifacts of global mean normalization. The study protocol met the approval of the local Ethics Committee, and all participants signed an informed consent form in compliance with the Helsinki Declaration of 1975.
Results
Main clinical, neuropsychological and 123 I-FP-CIT-SPECT data are reported in Table 1 . Among the 'first-line' assessments, PD þ RBD þ patients were more likely to have constipation (p ¼ 0.023) and showed worse olfaction (p ¼ 0.013) compared with PD þ RBD-. No other significant differences were found between the two groups.
Looking at the 'second-line' evaluation, PD þ RBD þ patients compared with PD þ RBD-patients were more likely to have MCI (p ¼ 0.026); as a group, they scored lower in all the cognitive domains but language. Moreover, PD þ RBD þ patients showed more severe nigro-striatal dopaminergic impairment compared with PD þ RBD-patients, mainly at caudate level. Fig. 1 shows Tukey boxplot of the significant neuropsychological and 123 I-FP-CIT-SPECT data comparisons between PD patients with and without RBD. Brain metabolism progressively decreased (height threshold p < 0.01 at voxel level with the family-wise error correction (FWE) for multiple comparisons) from controls to PD þ RBD-and to PD þ RBD þ patients in bilateral posterior cortical regions and in MAH frontal regions (FWE-corrected p < 0.001 at cluster level; Fig. 2A ; Supplemental Table S1 ).
Post-hoc analysis was conducted using the single SPM cluster achieving the highest z-scores, as reported in Supplemental  Table S1 (parietal-occipital regions, middle-temporal and angular gyrus of the MAH), and PD þ RBD þ patients showed significantly lower FDG uptake compared with PD þ RBD-patients (TukeyKramer method, p ¼ 0.015; Fig. 3 ). By contrast, relative increased metabolism was progressively found from controls to PD þ RBD-and to PD þ RBD þ patients in the frontal and prefrontal cortex, anterior cingulate, precentral gyrus and putamen of both hemisphere and in the amygdala, hippocampus/parahippocampal gyrus, middle/superior temporal gyrus, thalamus and caudate nucleus of the MAH (FWE-corrected p < 0.001 at cluster level; Fig. 2B ; Supplemental Table S2) .
Post-hoc analysis using the single SPM cluster achieving the highest z-scores, as reported in Supplemental Table S1 (anterior cingulate and precentral gyrus of the MAH) showed that PD þ RBD þ patients have significantly higher FDG uptake compared with PD þ RBD-patients (Tukey-Kramer method, p ¼ 0.048; Fig. 3 ).
To note, some small cerebral areas seem to have both increased and decreased metabolism (for example the MAH middle temporal gyrus). This effect could be due either to the peculiarities of ANOVA maps comparing three groups or to the deep location (i.e., white matter) of some relative hypermetabolic clusters which are indeed represented in pale red.
Discussion
In this study, we prospectively investigated a group of drug naïve patients with de novo PD. We divided the patients into two groups based on the clinical assessment of the presence of RBD (i.e., probable RBD). We compared clinical data of the conventional baseline visit in a movement disorders unit (i.e. 'first-line' evaluation) as well as neuropsychological and functional neuroimaging data obtained from a more detailed investigation (i.e. 'second-line' evaluation) between the two groups. In the first-line evaluation we found that patients with PD and probable RBD, compared with PD patients without RBD, showed only worse olfaction and more frequently had constipation while the UPDRS-III, the MMSE and the GDS-15 scores were not significantly different. However, on the 'second-line' assessment PD þ RBD þ patients exhibited a high prevalence of MCI, more severe nigro-striatal dopaminergic impairment and an altered brain glucose metabolism, mainly showing a posterior cortical hypometabolism.
These findings confirm and extend previous observations and add further features to the PD-RBD phenotype. In fact, autonomic dysfunction, including constipation, has been previously reported in PD patients with RBD [26] and hyposmia has been related to probable RBD [27] . Moreover, the presence of RBD in PD has been related to cognitive impairment [8] and a higher prevalence of MCI [28] . Extending previous data, in the present study these findings were found to be already present in a group of de novo, drug naïve PD patients. Furthermore, we recently reported that PD patients with RBD show a worse nigro-striatal dopaminergic functioning compared with PD patients without RBD [10] and the present data extend the finding in a patient sample with only partial overlap between the two cohorts.
PD þ RBD þ patients also showed a more severe hypometabolism, mainly in posterior cortical regions, including the parietal, occipital and posterior temporal regions, which is a novel finding confirming what previously found in iRBD patients [11] . Posterior association cortex hypometabolism has been suggested to reflect acetylcholine terminal deficit in patients with PD and especially in those with PD dementia and dementia with Lewy bodies and a strong topographic similarity has been observed between reduced glucose metabolism and impaired cholinergic activity [29] . In this line, posterior cortical hypometabolism in PD patients with probable RBD may suggest early cholinergic deficit as it was shown by means of 11 C-methylpiperidyl propionate acetylcholinesterase PET [30] . A relative FDG increased uptake in several cortical and sub-cortical regions has also been found in PD þ RBD þ patients in comparison with both PD þ RBD-patients and controls. This finding is in line with literature data in iRBD patients [11, 13] . When using global mean values for normalization during the SPM procedure, it is expected that the brain regions with mostly preserved or even slightly increased FDG uptake are depicted as relatively hypermetabolic, an issue that has been discussed and debated for long time [31] . In the present study, we used a higher grey matter threshold than default one to reduce this risk. Notwithstanding, the relatively hypermetabolic areas that we observed are similar to those described in the iRBD 'metabolic pattern' [11] . Although the present data demonstrate that PD patients with probable RBD showed a different brain metabolic pattern as compared with PD patients without RBD, the physiological interpretation of the present results is still difficult. Especially the finding of relative hypermetabolism appears mainly as an 'artifact' of global mean normalization in SPM procedure, and only quantitative PET studies could better clarify this issue.
It is intriguing to note that both motor severity of the disease, as evaluated by the UPDRS-III, and global cognitive status, as evaluated by the MMSE, were not different between PD þ RBDþ and PD þ RBD-patients. However, PD þ RBD þ patients, compared with PD þ RBD-patients, exhibited a more severe neuropsychological and brain imaging phenotype when a more detailed evaluation was carried out. This notion could be relevant to the everyday clinical practice. In fact, even if the 'first-line' evaluation (i.e., by means of simple scales such as the UPDRS-III and the MMSE) fails to disclose a malignant PD phenotype, the presence of a probable RBD, Table 1 Main demographic, clinical, neuropsychological and 123 I-FP-CIT-SPECT characteristics of the two PD groups (mean ± SD). identified by a simple and rapid clinical investigation, may represent a 'red flag'. Even a newly diagnosed PD patient with probable RBD is more likely to have a specific and more severe clinicalneuropsychological and functional neuroimaging phenotype. How much these functional neuroimaging characteristics and the presence of RBD are embedded in a phenotype carrying a worse prognosis, together with other features such as higher patient age, higher UPDRS motor axial score, and a lower categorical verbal fluency score for animals, recently outlined by Velseboer et al. [32] , requires a longer follow-up observation.
According to the diffuse/malignant PD phenotype proposed by Fereshtehnejad et al. [3] , in our study the presence of RBD was related to the presence of MCI and constipation. The PD þ RBD þ patients tended to have a higher prevalence of orthostatic hypotension, without reaching statistical significance, but this might be due to the relatively low number of patients, especially in the PD þ RBD-group. Moreover, blood pressure was automatically measured once and more accurate tests such as the tilting table procedure were not performed, which is a limitation of the study. F-FDG-PET. Results of ANOVA (SPM12; FWE corrected height threshold p < 0.01 at voxel level). A) Relative FDG decreased uptake. The brain regions reaching the statistical significance include the parietal-occipital regions, the middle-temporal and angular gyrus and the dorso-lateral prefrontal cortex and supplemental motor area of the more affected hemisphere (MAH; left side in the figure) and the posterior temporal lobe of the less affected hemisphere (right side in the figure) . B) Relative FDG increased uptake. The brain regions reaching the statistical significance include the frontal and prefrontal cortex, anterior cingulate, precentral gyrus and putamen of both hemisphere and in the amygdala, hippocampus/parahippocampal gyrus, middle/superior temporal gyrus, thalamus and caudate nucleus of the MAH.
It should also be noted there was a partial overlap between the two groups with all the clinical-neuropsychological and imaging modalities we used, thus suggesting a continuum between the two groups and that other factors may play a role. To note, all patients were in a very early stage of the disease, never treated with dopaminergic medication and with a relatively short duration of motor symptoms. Thus, all the alterations are expected in a mild form. Also, the overlap may partially derive from the main limitation of the present study, that is, RBD was not confirmed by the polysomnography. Although we still stress the crucial role of polysomnography in confirming RBD, MSQ has recently obtained 100% sensitivity and 95% specificity for the diagnosis of RBD in a community-based study [33] .
In conclusion, the main message of our study is that if in a patient who is firstly evaluated for PD we can identify the presence of probable RBD with a simple questionnaire and clinical interview in a standard clinical setting, then the diffuse/malignant subtype should be suspected. This finding can be confirmed by polysomnography, if feasible, and then a more detailed neuropsychological and possibly neuroimaging evaluation could confirm a more severe brain functional impairment than expected on the basis of the standard evaluation alone. This notion might prompt for more careful follow-up and eventually for vigorous intervention. Of course, this data needs to be replicated in larger and independent series.
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